Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of BAT8003 in Advanced Epithelial Cancer
NCT03884517Phase 1Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Mar 2019
- Primary completion
- Feb 2021
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT8003 (9 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-Limiting Toxicity at 3 weeks, Maximum Tolerated Dose at 3 weeks and 4 more. Started Mar 2019; status: terminated.
02
Drugs
BAT8003
Beyond the preview
Go deeper on NCT03884517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884517.